BAXERNA (www.baxerna.eu) is an EU-funded project that aims to develop next-generation mRNA vaccines against devastating bacterial infections like tuberculosis. The project consortium is led by researchers from VIB and UGent and includes multiple prominent European institutes, along with several innovative biotech companies. Together, these partners are developing effective and affordable vaccines using cutting-edge techniques, including immunopeptidomics, artificial intelligence, and nanomedicine. The top vaccine candidate against tuberculosis will be tested in a phase I clinical trial at Ghent University Hospital. With the combined expertise of its consortium, BAXERNA promises to revolutionize vaccine development against intractable bacterial pathogens.
Company Details
- Founded
- -
- Address
- Technologiepark-Zwijnaarde 75, Ghent,belgium
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.baxerna.eu/
- Keywords
- immunopeptidomics, LNPs, mRNA vaccines, Mycobacterium tuberculosis, Mycobacterium ulcerans, Acinetobacter baumannii, pharmaceutical freeze-drying, vaccine formulation, preclinical models, phase I clinical trial, immunology, GMP production.
- HQ
- Ghent
Baxerna Questions
Baxerna's website is https://www.baxerna.eu/
Baxerna's LinkedIn profile is https://be.linkedin.com/company/baxerna
Baxerna's industry is
Biotechnology Research
Baxerna's top competitors are
Vib,
Human Technopole,
Cper Resistomics,
Thermo Fisher Scientific,
T-One Therapeutics,
Althost Consortium,
Id-Antigens,
Baxter International Inc.,
Precivax Therapeutics,
Saeyslab.
Baxerna's categories are Biotechnology Research
Baxerna's founding year is 2023
